{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".31","upperLimit":".63","value":"0.44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"12-month progression-free survival is defined as the probability of patients remaining alive and progression-free at 12 months from study entry.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 6-8 cycles of bevacizumab and combination chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (A-CHOP) followed by 8 cycles of maintenance bevacizumab (MA), as outlined below. Bevacizumab 15 mg/kg is administered on day 1 over 90 min (first cycle), 60 min (second cycle) and 30 min for the subsequent cycles. CHOP (cyclophosphamide 750 mg/m 2 ; doxorubicin 50 mg/m 2 ; vincristine 1.4 mg/m2 \\[max. 2 mg\\]; prednisone 100 mg daily on days 1-5) is administered on day 1 of a 21-day cycle. Radiographic response is assessed after cycles 3, 6 and 8 of ACHOP and after cycle 8 of MA. Patients receive six cycles of ACHOP if they achieve a complete response (CR) after three cycles, eight cycles if they achieve a partial response (PR) after three cycles. Non-responders are removed from the study. ACHOP responders receive maintenance bevacizumab 15 mg/kg every 21 days for eight cycles.","id":"OG000","title":"Treatment (A-CHOP Followed by MA)"}],"paramType":"NUMBER","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months the first 2 years from study entry and every 6 months 3-5 years from study entry.","title":"12-Month Progression-Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"probability"}